Corporate / CVC
Every published round Sanofi took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
Companies Sanofi has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| No portfolio companies recorded yet. | ||||
Fund closes reported for Sanofi, as distinct from the investments it has made.
Companies Sanofi has backed that another company then bought. An exit for the holding, not a deal Sanofi did.
| Name | Role | Sources |
|---|---|---|
| Rebekah Cassidy | Deputy Head of Corporate Affairs and Sustainability, Australia & New Zealand (former) | @AuManufacturing |
Stories naming Sanofi. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Melbourne biotech ImmunoBiota courts investors for its still-open seed round around an oral Type 1 diabetes therapy; its recent Diabetes Australia award is recorded, while the flagged Series A and listing remain plans.
A Sydney research foundation has put funding into miRecule's next-generation therapy for facioscapulohumeral muscular dystrophy, which targets two disease mechanisms; the biotech hopes to run early trials in Australia.
Melbourne biotech Aravax, developer of the peanut allergy immunotherapy PVX108, adds former ALK-Abello chief Carsten Hellmann and ex-Aimmune commercial head Andrew Oxtoby to its board ahead of Phase 3.
Sanofi is buying Vicebio for up to US$1.6 billion in the biggest-ever exit of Australian university IP, with UQ keeping equity; the article also recalls the Inflazome and Spinifex sales and Vicebio's Medicxi seed.
Roundup covering manufacturing placements by Sparc Technologies and Aurora Labs, Wellnex's planned London listing, an autonomous navy boat trial, a workplace fine, a software degree launch and AusBiotech's next CEO.